BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9765623)

  • 21. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
    Harker WG; Slade DL; Parr RL; Holguin MH
    Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
    Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
    Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers.
    Ochiai M; Oguri T; Isobe T; Ishioka S; Yamakido M
    Jpn J Cancer Res; 1999 Dec; 90(12):1338-43. PubMed ID: 10665651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
    Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
    Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The small GTPase RhoA has greater expression in small cell lung carcinoma than in non-small cell lung carcinoma and contributes to their unique morphologies.
    Varker KA; Phelps SH; King MM; Williams CL
    Int J Oncol; 2003 Mar; 22(3):671-81. PubMed ID: 12579323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
    Staley BE; Samowitz WS; Bronstein IB; Holden JA
    Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
    Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
    Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.
    Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ
    Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
    Bauman ME; Holden JA; Brown KA; Harker WG; Perkins SL
    Mod Pathol; 1997 Mar; 10(3):168-75. PubMed ID: 9071722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.
    Uesaka T; Shono T; Kuga D; Suzuki SO; Niiro H; Miyamoto K; Matsumoto K; Mizoguchi M; Ohta M; Iwaki T; Sasaki T
    J Neurooncol; 2007 Sep; 84(2):119-29. PubMed ID: 17361331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
    Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
    Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
    Holden JA; Townsend JJ
    Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
    Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
    Lynch BJ; Komaromy-Hiller G; Bronstein IB; Holden JA
    Hum Pathol; 1998 Nov; 29(11):1240-5. PubMed ID: 9824101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.
    Sakurai R; Kaira K; Miura Y; Sunaga N; Saito R; Oyama T; Hisada T; Yamada M
    Thorac Cancer; 2020 Feb; 11(2):426-435. PubMed ID: 31901017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
    Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
    Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
    Monnin KA; Bronstein IB; Gaffney DK; Holden JA
    Hum Pathol; 1999 Apr; 30(4):384-91. PubMed ID: 10208458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of placental growth factor gene in lung cancer.
    Woo IS; Park MJ; Byun JH; Hong YS; Lee KS; Park YS; Lee JA; Park YI; Ahn HK
    Tumour Biol; 2004; 25(1-2):1-6. PubMed ID: 15192305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
    Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.